More on HNSBF
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.70 |
|
|||
| Open | $3.70 | ||||
| 52 Wk High | $10.40 | ||||
| 52 Wk Low | $3.21 | ||||
| Day High | $3.70 | ||||
| Day Low | $3.70 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 7,100 | ||||
- Wedbush Starts Hansa Biopharma AB (HNSA:SS) (HNSBF) at Outperform
- Why Jefferies sees these stocks as standout biotech plays in 2026
- Hansa Biopharma AB (HNSA:SS) (HNSBF) PT Lowered to SEK93 at Leerink Partners
- Hansa Biopharma's imlifidase meets primary endpoint in Phase 3 kidney trial
- Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
Entities mentioned with HNSBF
- FDA | View Related Stories »
- JPMorgan | View Related Stories »
- UBS | View Related Stories »
- BofA/Merrill Lynch | View Related Stories »
- Definitive Agreement | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
